Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | NCF1 | P14598 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAD52 | P43351 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1106429 | 0.83 | ALDH1A1 (0.36) | ALDH1A1L3MBTL1L3MBTL3PIM1TGM2 | |
| SCHEMBL3436969 | 0.78 | L3MBTL1 (0.46) | ALDH1A1L3MBTL1L3MBTL3PIM1VCP | |
| SCHEMBL24170436 | 0.78 | HRH4 (0.31) | ALDH1A1KDM4E | |
| SCHEMBL21214477 | 0.77 | L3MBTL1 (0.36) | ALDH1A1L3MBTL1L3MBTL3PIM1SIGMAR1 | |
| SCHEMBL13439368 | 0.77 | KDM4E (0.41) | ALDH1A1L3MBTL1L3MBTL3PIM1SIGMAR1 | |
| SCHEMBL14805853 | 0.76 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1L3MBTL3PIM1 | |
| SCHEMBL18369768 | 0.76 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1L3MBTL3PIM1 | |
| SCHEMBL12881594 | 0.76 | SIGMAR1 (0.43) | ALDH1A1L3MBTL1L3MBTL3TGM2SIGMAR1 | |
| SCHEMBL23269640 | 0.75 | L3MBTL1 (0.44) | ALDH1A1L3MBTL1L3MBTL3PIM1VCP | |
| SCHEMBL22519024 | 0.75 | L3MBTL1 (0.41) | ALDH1A1L3MBTL1L3MBTL3PIM1VCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026840-A1 | COMPOUND USED AS EGFR KINASE INHIBITOR AND USE THEREOF | TYK MEDICINES, INC. (CN) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026840-A1 | COMPOUND USED AS EGFR KINASE INHIBITOR AND USE THEREOF | EGFR, ERBB2, ERBB4 | ALDH1A1 3668/4885L3MBTL1 3958/4885L3MBTL3 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.